These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 31418022)

  • 1. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
    Schwarz TF; McPhee RA; Launay O; Leroux-Roels G; Talli J; Picciolato M; Gao F; Cai R; Nguyen TL; Dieussaert I; Miller JM; Schmidt AC
    J Infect Dis; 2019 Oct; 220(11):1816-1825. PubMed ID: 31418022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
    Langley JM; Aggarwal N; Toma A; Halperin SA; McNeil SA; Fissette L; Dewé W; Leyssen M; Toussaint JF; Dieussaert I
    J Infect Dis; 2017 Jan; 215(1):24-33. PubMed ID: 27694633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
    Beran J; Lickliter JD; Schwarz TF; Johnson C; Chu L; Domachowske JB; Van Damme P; Withanage K; Fissette LA; David MP; Maleux K; Schmidt AC; Picciolato M; Dieussaert I
    J Infect Dis; 2018 Apr; 217(10):1616-1625. PubMed ID: 29401325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 study.
    Baker J; Aliabadi N; Munjal I; Jiang Q; Feng Y; Brock LG; Cooper D; Anderson AS; Swanson KA; Gruber WC; Gurtman A
    Vaccine; 2024 May; 42(13):3172-3179. PubMed ID: 38616438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study.
    Leroux-Roels G; De Boever F; Maes C; Nguyen TL; Baker S; Gonzalez Lopez A
    Vaccine; 2019 May; 37(20):2694-2703. PubMed ID: 30987852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase 1 Clinical Trial in Healthy Older Adults.
    Shaw CA; Essink B; Harper C; Mithani R; Kapoor A; Dhar R; Wilson L; Guo R; Panozzo CA; Wilson E; Simorellis AK; Reuter C; Stoszek SK; Chen GL; Das R; Goswami J
    J Infect Dis; 2024 Sep; 230(3):e647-e656. PubMed ID: 38385566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
    August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
    Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Immunogenicity of a Respiratory Syncytial Virus Fusion (F) Protein Nanoparticle Vaccine in Healthy Third-Trimester Pregnant Women and Their Infants.
    Muňoz FM; Swamy GK; Hickman SP; Agrawal S; Piedra PA; Glenn GM; Patel N; August AM; Cho I; Fries L
    J Infect Dis; 2019 Oct; 220(11):1802-1815. PubMed ID: 31402384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
    Bebia Z; Reyes O; Jeanfreau R; Kantele A; De Leon RG; Sánchez MG; Banooni P; Gardener GJ; Rasero JLB; Pardilla MBE; Langley JM; Di Leo CM; Botelho-Nevers E; Buttery J; Laurichesse H; Madhi SA; García AM; Stanley T; Barjat T; Griffith R; Castrejón-Alba MM; de Heusch M; Dieussaert I; Hercor M; Lese P; Qian H; Tullio AN; Henry O
    J Infect Dis; 2023 Aug; 228(3):299-310. PubMed ID: 36722147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material.
    Jastorff A; Bastian AR; Ligtenberg N; Klyashtornyy V; Callendret B; Heijnen E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2383504. PubMed ID: 39118413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, and Immunogenicity of an mRNA-Based Respiratory Syncytial Virus Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
    Shaw CA; Mithani R; Kapoor A; Dhar R; Wilson L; El Asmar L; Schnyder-Ghamloush S; Schaefers K; August A; Stoszek SK; Chen GL
    J Infect Dis; 2024 Sep; 230(3):e637-e646. PubMed ID: 38298125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF-Based Regimen in Japanese Adults Aged 60 Years and Older.
    Eto T; Okubo Y; Momose A; Tamura H; Zheng R; Callendret B; Bastian AR; Comeaux CA
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13336. PubMed ID: 38880785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
    Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
    J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial.
    Schwarz TF; Hwang SJ; Ylisastigui P; Liu CS; Takazawa K; Yono M; Ervin JE; Andrews CP; Fogarty C; Eckermann T; Collete D; de Heusch M; De Schrevel N; Salaun B; Lambert A; Maréchal C; Olivier A; Nakanwagi P; Lievens M; Hulstrøm V
    J Infect Dis; 2024 Jul; 230(1):e102-e110. PubMed ID: 39052726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life.
    Hosman T; van Heesbeen R; Bastian AR; Hu W; Comeaux C; Ligtenberg N; van Montfort B; Callendret B; Heijnen E
    Hum Vaccin Immunother; 2024 Dec; 20(1):2344970. PubMed ID: 38783590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study.
    Langley JM; MacDonald LD; Weir GM; MacKinnon-Cameron D; Ye L; McNeil S; Schepens B; Saelens X; Stanford MM; Halperin SA
    J Infect Dis; 2018 Jul; 218(3):378-387. PubMed ID: 29617814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
    Walsh EE; Falsey AR; Zareba AM; Jiang Q; Gurtman A; Radley D; Gomme E; Cooper D; Jansen KU; Gruber WC; Swanson KA; Schmoele-Thoma B
    J Infect Dis; 2024 Oct; 230(4):e905-e916. PubMed ID: 38606958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
    Hermida N; Ferguson M; Leroux-Roels I; Pagnussat S; Yaplee D; Hua N; van den Steen P; Anspach B; Dieussaert I; Kim JH
    J Infect Dis; 2024 Aug; 230(2):e353-e362. PubMed ID: 38133639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.